Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Cat . Non | Espèces | Description du produit | Structure | Pureté | Caractéristique |
---|---|---|---|---|---|
RAS-SP010 | Mouse | Mouse IL-4 ELISPOT Kit | |||
GMP-L04H26 | Human | GMP Human IL-4 Protein |
|
||
IL4-H5253 | Human | Human IL-4 Protein, Fc Tag (MALS verified) |
|
||
CRS-B003 | Human | ClinMax™ Human IL-4 ELISA Kit | |||
EP-132 | Human | IL-4 [Biotinylated] : IL-4Rα Inhibitor Screening ELISA Kit | |||
CRS-A004 | Human | resDetect™ Human Interleukin-4 (IL-4) ELISA Kit (Residue Testing) | |||
IL4-H52H9 | Human | Human IL-4 Protein, His Tag (MALS verified) |
|
||
IL4-C5259 | Cynomolgus | Cynomolgus IL-4 Protein, Fc Tag (MALS verified) |
|
||
IL4-M52H5 | Mouse | Mouse IL-4 Protein, His Tag |
|
||
IL4-H82E0 | Human | Biotinylated Human IL-4 Protein, Avitag™,His Tag (MALS verified) |
|
||
IL4-H4218 | Human | Human IL-4 Protein, premium grade |
|
GMP Human IL-4 Protein (Cat. No. GMP-L04H26) stimulates proliferation of TF-1 human erythroleukemic cell line. The specific activity of GMP Human IL-4 Protein is > 1.20×10^7 IU/mg, which is calibrated against human IL-4 WHO International Standard (NIBSC code: 88/656) (QC tested).
INHIBITION OF IL-4 [BIOTINYLATED]: IL-4 R ALPHA BINDING BY Human IL-4
Serial dilutions of Human IL-4(Catalog # EP132-C03) (1:1 serial dilution, from 5 μg/mL to 0.01 μg/mL (295.86-0.58 nM)) was added into IL-4 R alpha: IL-4-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
The purity of Human IL-4 Protein, Fc Tag (Cat. No. IL4-H5253) is more than 90% and the molecular weight of this protein is around 90-110 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Berdazimer sodium-SB-206 (Novan) | NVN-1000-SB-206-Novan; MAP3-NONOate - SB-206; NVN1000-SB206; SB-206; SB-019; NI-MC101 | Approved | Zelsuvmi, ZELSUVMI, KINSOLUSTM | United States | Molluscum Contagiosum | Lnhc Inc | 2024-01-05 | Acne Vulgaris; Tinea Pedis; Psoriasis; Molluscum Contagiosum; Condylomata Acuminata; Dermatitis, Atopic | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Berdazimer sodium-SB-204 (Novan) | MAP3-NONOate-SB-204; NVN1000-SB204; SB-204 | Phase 3 Clinical | University Of North Carolina At Chapel Hill | Acne Vulgaris | Details |
Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | Details |
Dectrekumab/VAK-694 | QBX-258 | Phase 2 Clinical | Novartis Pharma Ag | Lymphedema; Asthma | Details |
OCH-NCNP1 | OCH-NCNP1 | Phase 2 Clinical | Keio University | Multiple Sclerosis; Crohn Disease | Details |
PF-07264660 | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
PF-07275315 | PF-07275315 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
AUP1602-C | AUP-16; AUP1602-C | Phase 2 Clinical | Aurealis | Diabetic Foot; Ulcer | Details |
KBL-693 | KBL-693 | Phase 1 Clinical | Kobiolabs | Asthma | Details |
This web search service is supported by Google Inc.